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Paternal drug use: before and
during pregnancy
Ineke Crijns†, Jens Bos, Marissa Knol, Sabine Straus &
Lolkje de Jong-van den Berg
†University of Groningen, Department of PharmacoEpidemiology & PharmacoEconomics,
Groningen, The Netherlands
Objective: Exploratory investigation on drug use by fathers before and during
pregnancy with regard to the number of pregnancies.
Research design and methods: Data of Dutch community pharmacies were
used in which fathers were linked to children. The prevalence of the 15 most
prescribed drug groupswere calculated per trimester for one trimester precon-
ception and three trimesters during pregnancy. Drugs with possible harmful
effect on the semen and/or embryo based on recent safety issues were
analyzed for two trimesters before conception. Descriptive statistics was used.
Results: During the four trimesters, fathers had used one or more drugs in
73% of the pregnancies. Per trimester, drug use ranged from 35 to 39%,
with the highest prevalence in the third trimester, statistically significant for
the use of one or two drugs. Drugs used most frequently belong to ‘anti-
inflammatory and antirheumatic products’. Drugs such as SSRIs with possible
harmful effect on the semen and/or embryo are used in 1.4% by fathers
before conception.
Conclusion: A proportion of 73% of fathers used drugs before and during
pregnancy, increasing toward the third trimester. To increase the knowledge
on possible effects, organizations like EUROCAT and (EN)(O)TIS might be
encouraged to also collect paternal drug use.
Keywords: drugs, paternal, pregnancy, teratogenicity
Expert Opin. Drug Saf. (2012) 11(4):513-518
1. Introduction
Little is known of the influence of paternal drug exposure on pregnancy outcome.
There is some evidence that some medicinal products used by male patients can
effect fertility or embryo toxicity [1]. Use of drugs preconception by fathers might
be of influence on the offspring due to different mechanisms such as presence of
the drug in seminal fluid and genetic or epigenetic action with direct influence on
the spermatogenesis. Presence of drugs in seminal fluid could interfere with embry-
onic or fetal development because of a direct effect on the uterus or the vaginal
mucosa during sexual intercourse [1,2] during pregnancy. Certain drugs for onco-
logic indications such as cyclophosphamide, and 6-mercaptopurine have been
known for their negative effect on sperm quality [1]. Children of fathers who sur-
vived cancer had more major congenital anomalies than children whose father did
not have a history of cancer [3].
Recently, it was detected that a-reductase inhibitors dutasteride and finasteride
cause a decline in sperm quality by decrease of the blood level of dihydrotestoster-
one [4]. Another study showed abnormal DNA fragmentation in sperm caused by
paroxetine [5]. Abnormal DNA fragmentation can lead to diminished fertility and
is associated with an increased risk of diseases in the offspring [6].
A drug utilization study [7] using Dutch as well as Danish drug prescription data
showed that approximately one-third of the fathers used medicinal products
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6 months before conception. A publication from Norway [8],
showed drug use by 25% of the fathers in 3 months before
conception. Teratology Information Services (TIS) [9-11]
report that approximately 0.2 -- 2% of the questions concern
paternal exposure.
During the recent years, there have been discussions on the
effects on semen and/or offspring regarding frequently used
drugs by fathers. Regulatory authorities had reason for con-
cern regarding drug use by fathers based on studies and case
reports for products such as selective serotonin reuptake
inhibitors (SSRIs) [5] and finasteride [4].
Spermatogenesis takes approximately 74 days [12]. To cover
the susceptible period, the data of at least 3 months precon-
ception should be used for information on paternal drug use.
Studies on congenital anomalies focus merely on drug use by
mothers. This is similar for pregnancy registries or congenital
anomaly databases for collecting data on drug use by mothers.
This was reason for investigating drug use among fathers.
The aim of this study is to explore the use of medicinal
products by fathers before and during pregnancy. The
main question was: which drug groups are most frequently
prescribed to fathers in the 3 months before and during
pregnancy. Secondary, the use of drugs of concern was
investigated for 6 months prior conception only, because
of the known influence on the sperm quality.
2. Materials and methods
2.1 Database
For this study, data of Dutch community pharmacies
obtained from the InterAction DataBase (IADB.nl) [13] are
used. IADB.nl is a database containing prescriptions of a
population of approximately 500,000 individuals from the
Netherlands. The data consist of among others personal charac-
teristics (an anonymous identifier, gender and date of birth)
and for drugs the Anatomical Therapeutical Chemical (ATC)
code [14], the dispensing date, the number of days the prescription
is valid and the prescriber [15].
Because Dutch patients commonly register with one
pharmacy and mainly obtain their prescription medication
from this pharmacy; medication histories of patients can be
considered nearly complete [16].
In the database, fathers were linked to children by selecting
children between 0 and 5 years of age and males 15 and
50 years older than the child and registered on the same
address under the condition that there is only one male person
of this age group registered on this address. Situations with
more than one male 15 -- 50 years of age present at the
same address of the linked child were excluded.
For this study, prescription data covering the period of
1994 up to and including 2009 are used.
Prevalence of drug use is measured per trimester (91 days).
Prevalence per trimester is defined as the number of fathers
with at least one prescription of drug(s), divided by the num-
ber of pregnancies. One trimester before conception and the
three trimesters during pregnancy were studied. Date of
conception is defined as 273 days before birth date of child.
The prevalence of the 15 most prescribed drug groups per
trimester were calculated.
Use of drugs with a possible harmful effect on semen
and/or the embryo by fathers were tabled for two trimesters
before conception and calculated over these 6 months. The
selection of these drugs, sulfasalazine, finasteride, mercapto-
purine, leflunomide and SSRIs, was based on recent safety
issues regarding the use by (potential) fathers [2,4,5].
2.2 Statistics
Descriptive statistics are used to calculate the prevalence of the
number of pregnancies in which the father used one or more
medicinal products. Also the prevalence with 95% confidence
interval (95%CI) of the 15most prescribed drug groups per tri-
mester as percentage of pregnancies in which the father used one
or more drugs of this therapeutic group in the certain trimester.
3. Results
For the period of 1994 -- 2009, the database contained data of
25,954 pregnancies for which information of fathers was
available. The number of pregnancies linked to fathers using
one or more drugs are presented in Table 1 and Figure 1.
A total of 7745 out of 18,209 fathers were includedmore than
once during the study period, because of multiple pregnancies.
During the four trimesters, in 18,841 (73%) of the preg-
nancies fathers had used one or more drugs. The prevalence
of drug use per trimester varies between 34.9 and 38.8%.
The highest prevalence (38.8%) is in the third trimester of
pregnancy which is statistically significant compared with
the trimester before pregnancy.
The 15 most prescribed therapeutic drugs to men fathered
a child, based on the ATC mean groups, sorted by frequency
of use before conception are presented in Table 2. The order is
almost similar for all trimesters.
Drugs prescribed to fathers with the highest prevalence
belong to the therapeutic drug group of ‘anti-inflammatory
and antirheumatic products’ (ATC = M01), followed by
‘antibacterials for systemic use’ (ATC = J01), ‘corticosteroid,
dermatological preparations’ (ATC = D07) and ‘drugs for
acid-related disorders’ (ATC = A02). These drugs, except for
‘drugs for acid-related disorders’ also have the highest prevalence
in the third trimester.
Drugs for which there have been safety issues on fertility,
semen disorders or congenital anomalies regarding use by
fathers are presented in Table 3.
4. Discussion
The highest prevalence of drugs prescribed to fathers was
observed during the third trimester of the pregnancy. How-
ever, individual drug groups may show a different pattern of
use. Drugs with safety issues on fertility or semen disorders
concerns 1 -- 1.5% of the fathers.
I. Crijns et al.



























































Table 1. Number of pregnancies in which the father used one or more medicinal products, in the defined
trimesters with a total number of pregnancies of 25,954.
Preconception
(-3 to 0 months)
First trimester
(1 -- 3 months)
Second trimester
(4 -- 6 months)
Third trimester
(7 -- 9 months)
n (%) n (%) n (%) n (%)
Number of pregnancies in which the
father used one or more medicinal
products during the specific period
9073 (35.0) 9062 (34.9) 9501 (36.6) 10066 (38.8)
One type of medicinal product 5258 (57.9) 5363 (59.2) 5493 (57.8) 5853 (58.1)
Two types of medicinal products 2209 (24.3) 2108 (23.3) 2317 (24.4) 2427 (24.1)
Three types of medicinal products 884 (9.7) 910 (10.0) 963 (10.1) 1001 (9.9)
Four types of medicinal products 399 (4.4) 359 (4.0 394 (4.1) 413 (4.1)











Preconception First trimester Second trimester Third trimester
Figure 1. Number of pregnancies in which the father used one or more drugs during the specific period.
Table 2. Top 15 of most prescribed therapeutic medicinal product groups by fathers sorted on the first trimester
following birth (n = 25,955 pregnancies).
ATC Therapeutic drug group Preconception Trimester 1 Trimester 2 Trimester 3
% (95% CI) % (95% CI) % (95% CI) % (95% CI)
1 M01 Anti-inflammatory and antirheumatic products 6.0 (5.7 -- 6.3) 6.0 (5.7 -- 6.3) 6.8 (6.5 -- 7.1)* 6.8 (6.5 -- 7.1)*
2 J01 Antibacterials for systemic use 5.8 (5.5 -- 6.1) 5.8 (5.5 -- 6.0) 5.8 (5.5 -- 6.1) 6.5 (6.2 -- 6.8)*
3 D07 Corticosteroids, dermatological preparations 4.0 (3.8 -- 4.2) 4.0 (3.8 -- 4.3) 4.0 (3.7 -- 4.2) 4.5 (4.2 -- 4.7)
4 A02 Drugs for acid-related disorders 3.2 (3.0 -- 3.4) 3.1 (2.9 -- 3.3) 3.3 (3.1 -- 3.5) 3.5 (3.3 -- 3.8)
5 R01 Nasal preparations 3.0 (2.8 -- 3.2) 2.9 (2.7 -- 3.1) 3.4 (3.1 -- 3.6) 3.4 (3.2 -- 3.6)
6 R03 Drugs for obstructive airway diseases 3.0 (2.8 -- 3.2) 2.9 (2.7 -- 3.1) 3.3 (3.0 -- 3.5) 3.3 (3.0 -- 3.5)
7 R06 Antihistamines for systemic use 2.7 (2.5 -- 2.9) 2.7 (2.5 -- 2.9) 2.8 (2.6 -- 3.0) 3.0 (2.9 -- 3.3)
8 N05 Psycholeptics 2.6 (2.4 -- 2.7) 2.5 (2.3 -- 2.7) 2.6 (2.4 -- 2.8) 2.9 (2.7 -- 3.1)
9 D01 Antifungals for dermatological use 2.3 (2.1 -- 2.5) 2.4 (2.2 -- 2.6) 2.6 (2.4 -- 2.8) 2.8 (2.6 -- 3.0)*
10 S01 Ophthalmologicals 2.2 (2.0 -- 2.4) 2.4 (2.2 -- 2.6) 2.5 (2.3 -- 2.7) 2.6 (2.4 -- 2.8)*
11 N02 Analgesics 2.1 (1.9 -- 2.2) 2.1 (1.9 -- 2.3) 2.1 (1.9 -- 2.2) 1.9 (1.7 -- 2.1)
12 N06 Psychoanaleptics 2.0 (1.8 -- 2.1) 2.1 (1.9 -- 2.3) 2.2 (2.0 -- 2.3) 2.3 (2.1 -- 2.5)
13 D02 Emollients and protectives 1.1 (1.0 -- 1.3) 1.0 (0.9 -- 1.2) 1.1 (1.0 -- 1.3) 1.2 (1.1 -- 1.4)
14 R05 Cough and cold preparations 1.1 (1.0 -- 1.2) 1.1 (1.0 -- 1.2) 1.2 (1.1 -- 1.3) 1.2 (1.1 -- 1.3)
15 A10 Drugs used in diabetes 0.8 (0.7 -- 0.8) 0.8 (0.6 -- 0.9) 0.8 (0.7 -- 0.9) 0.9 (0.8 -- 1.0)
*Prevalence is significantly higher, compared the preconception.
ATC: Anatomical Therapeutical Chemical code; CI: Confidence interval.
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It is to be expected that chronically used drugs such as anti-
rheumatic drugs, antidiabetics or drugs for obstructive airway
diseases remain stable during the period of pregnancy. This
was more or less the matter for the latter two drug groups.
For the drug group ‘anti-inflammatory and antirheumatic
drugs’, however, there was a significant increase from the sec-
ond trimester during pregnancy onwards. Explanations for
this phenomenon should be investigated.
Approximately 6% of the fathers use anti-inflammatory
and antirheumatic drugs despite that only 0.7% of the male
Dutch population suffers from rheumatic arthritis [17]. It
seems that these drugs are more widely used. It is known
that non-steroidal anti-inflammatory drugs (NSAIDs) are
used as painkillers in general. A study on drug use for rheuma-
toid arthritis peri-pregnancy in both mothers and fathers
showed that the use of these drugs among fathers was 0.8%
in the 3 months before conception [18]. Antirheumatic drugs
use in fathers in this study [18] was NSAIDs by 53% and pred-
nisolone by 27%; showing that drugs with a known (human)
teratogenicity are seldom prescribed for fathers.
During the third trimester of pregnancy there was an
increased use of psycholeptics (including antipsychotic and
anxiolytic drugs) while psychoanaleptics (including antide-
pressants) did show a steady increase over all trimesters.
Psychological stress in first-time expecting fathers [19] might
explain the increase of psycholeptic drug use. The increase
of psychoanaleptics during pregnancy should be investigated,
however Paulson and Bazemore [20] showed a higher preva-
lence of depression during pregnancy in expecting fathers
compared with the overall prevalence of depression in
men, but the highest depression rates in men were seen
3 -- 6 months postpartum.
Comparing our study results with previous drug prescription
studies [7,8] among fathers in the trimester before conception, we
found in the IADB population approximately 2 -- 2.8 times
higher use for corticosteroids, dermatological preparations,
drugs for acid-related disorders, drugs for obstructive airway
diseases, psycholeptics and antifungals for dermatological use
(Table 4). For drug groups for chronic use, such as drugs used
for diabetes, obstructive airway diseases and musculoskeletal
disorders it was more or less similar (Table 4).
The products with a possible harmful effect on fertility
and/or the embryo did not belong to the top 15 drug groups
used by fathers except the SSRIs.
Limitation of the study is the indirect link between fathers
and children. However, it may be presumed that eventual
misclassification of the father will be very limited. The effect
on the data might be negligible because prescribing drugs to
fertile male patients mostly lacks caution. Furthermore, infor-
mation on drugs obtained during hospital stay or over-the-
counter drugs is not included in the database which can result
in underestimation of drug use.
There have been investigations on fathers exposed to herbi-
cides, pesticides, radiation and other occupational exposures
and effects to offspring, whether decreased fertility, spontane-
ous abortions, prematurity or congenital anomalies, but expo-
sure to drugs is hardly investigated. Besides investigating
maternal drug exposure, paternal drug exposure should also
be investigated. The data available on paternal drug exposure
deal mainly with impaired fertility and sperm abnormalities.
There is scarce information on paternal drug exposure and
congenital anomalies. There are some studies about the risk of
congenital anomalies in the offspring of fathers with a history
of cancer. A cohort study [3] with data from the Danish and
Swedish Birth registries linked with Danish and Swedish cancer
registries, hospital discharge registers and congenital anomaly
registers showed that there is a significant increase in the risk
of major congenital anomalies in children from fathers with a
history of cancer. However, a study [21] in fathers who survived
childhood cancer did not identify adverse outcomes in the
offspring of fathers treated with chemotherapy in childhood.
There is only limited literature on paternal exposure to spe-
cific drugs, either case reports or small cohort studies. Publica-
tions identified were on methotrexate [22], lamuvidine [23],
thiopurines [2,24] such as mercaptopurine [25] and azathio-
prine, ribavirin [26] and the combination of ribavirin--IFN-
a B2 combination [27], antirheumatics [18] such as methotrex-
ate, sulfasalazin and biologics, finasteride [28], paroxetine [5]
and testosterone gel [29]. The results of these studies are often
contradictive. For instance, two studies on mercaptopurine
use by fathers report an increase of pregnancy-related compli-
cations [25] or congenital anomalies [2] while another study
found no increased risk [24].
An Editorial in 1992 by Davis et al. [30] concluded that
because of the absence of records regarding prefertilization
paternal exposures and their confrontation with adverse preg-
nancy and antenatal health outcomes detailed information on
prefertilization exposures of both parents should be obtained.
Also Lee et al. [11] concluded that there is an ongoing need for
Table 3. Six months prevalence of drugs in fathers
with recent safety issues regarding use by fathers.
ATC Drug 6 months
preconception
N (per 1000)
A07EC01 Sulfasalazine 15 (0.6)
D11AX10 Finasteride 1 mg 6 (0.2)




N06AB SSRI 354 (13.6)
N06AB03 Fluoxetine 54 (2.1)
N06AB04 Citalopram 37 (1.4)
N06AB05 Paroxetine 188 (7.2)
N06AB06 Sertraline 19 (0.7)
N06AB08 Fluvoxamine 53 (2.0)
N06AB10 Escitalopram 3 (0.1)
ATC: Anatomical Therapeutical Chemical code; SSRI: Selective serotonin
reuptake inhibitor.
I. Crijns et al.



























































information on paternal drug exposure. The majority of the
published studies and case reports so far are from TIS of coun-
tries with birth registries. It should be noted that organizations
like (EN)(O)TIS have few data on paternal exposure because
maternal exposure is more obvious. In addition, gynecologists,
midwives and general practitioners should encourage counseling
on paternal exposure besides maternal exposure.
5. Conclusions
A large proportion of fathers used drugs before and during
pregnancy with an increase toward the third trimester.
Reason for certain patterns in use and specifically the
increase for the total use in the third trimester have to be
investigated. To increase the knowledge on possible pater-
nal contribution to congenital anomalies, organizations
like EUROCAT and (EN)(O)TIS might be encouraged to
collect information on paternal drug use before and
during pregnancy.
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Table 4. Number of prescriptions to fathers over the last 3 months before conception.
ATC Therapeutic drug group IADB
% (95% CI)
Engeland
et al. 2008 8
% (95% CI)
Schirm




et al. 2004 7*
DK data
% (95% CI)
M01 Anti-inflammatory and antirheumatic products 6.0 (5.7 -- 6.3) 5.6 (5.5 -- 5.8) 7.6 (6.8 -- 8.3){ 6.1 (5.9 -- 6.3)
J01 Antibacterials for systemic use 5.8 (5.5 -- 6.1) 5.8 (5.6 -- 5.9) 6.3 (5.7 -- 6.9) 14.3 (14.0 -- 14.6){
D07 Corticosteroid, dermatological preparations 4.0 (3.8 -- 4.2)# 1.7 (1.5 -- 1.8) -- --
A02 Drug for acid-related disorders 3.2 (3.1 -- 3.4)# 1.4 (1.3 -- 1.5) 2.5(2.2 -- 3.0) 1.6 (1.5 -- 1.8)
R01 Nasal preparations 3.0 (2.8 -- 3.2)# 2.5 (2.5 -- 2.6) -- --
R03 Drugs for obstructive airway diseases 3.0 (2.8 -- 3.2)# 1.9 (1.8 -- 2.0) -- --
R06 Antihistamines for systemic use 2.7 (2.5 -- 2.9) 3.2 (3.1 -- 3.3){ 2.0 (1.7 -- 2.4)** 2.0 (1.9 -- 2.1)**
N05 Psycholeptics 2.6 (2.4 -- 2.7)zz 1.8 (1.7 -- 1.8) 2.0 (1.7 -- 2.5) 0.3 (0.3 -- 0.4)
D01 Antifungals for dermatological use 2.3 (2.1 -- 2.5)# 0.8 (0.7 -- 0.8) -- --
S01 Ophthalmologicals 2.4 (2.2 -- 2.6) -- -- --
N02 Analgesics 2.1 (1.9 -- 2.3) 2.6z (2.5 -- 2.7){ 3.4 (3.0 -- 3.9){ 1.3 (1.2 -- 1.4)**
N06 Psychoanaleptics 2.1 (1.9 -- 2.3)# 1.4§ (1.3 -- 1.4) 1.3 (1.0 -- 1.6) 0.4 (0.4 -- 0.5)
R05 Cough and cold preparations 1.1 (1.0 -- 1.2) 1.3 (1.3 -- 1.4) 1.7 (1.4 -- 2.0){ 0.3 (0.3 -- 0.4)**
D02 Emollients and protectives 1.0 (0.9 -- 1.2) -- -- --
A10 Drugs used in diabetes 0.8 (0.7 -- 0.9)# 0.6 (0.6 -- 0.7) 0.5 (0.4 -- 0.7) 0.6 (0.5 -- 0.6)
*Six months prior conception.
zRestricted to ATC N02A, opioids.
§Restricted to ATC N06A, antidepressants.
{Statistically significant higher than the current study.
#Current study statistically significant higher.
**Statistically significant lower than the other studies.
zzStatistically significant higher than the studies of Engeland or the DK data.
ATC: Anatomical Therapeutical Chemical code; CI: Confidence interval; IADB: InterAction DataBase.
NL data: IADB.nl data.
DK data: Pharmacoepidemiological prescription database of North Jutland in Denmark.
Paternal drug use around pregnancy




























































Papers of special note have been highlighted as
either of interest () or of considerable interest
() to readers.
1. Trasler JM, Doerksen T. Teratogen
update: paternal exposures-reproductive
risks. Teratology 1999;60:161-72
. Basic knowledge, excellent overview.
2. Nørgard B, Pedersen L, Jacobsen J, et al.
The risk of congenital abnormalities in
children fathered by men treated with
azathioprine or mercaptopurine before
conception. Aliment Pharmacol Ther
2004;19:679-85
. Created awareness on the risks of
congenital anomalies by paternal
drug use.
3. Stahl O, Boyd H, Giwercman A, et al.
Risk of birth abnormalities in the
offspring of men with history of cancer:
a cohort study using Danish and Swedish
National Registries. J Natl Cancer Inst
2011;103:398-406
4. Amory JK, Wang C, Swerdloff RS, et al.
The effect of 5alpha-reductase inhibition
with dutasteride and finasteride on semen
parameters and serum hormones in
healthy men. J Clin Endocrinol Metab
2007;92:1659-65
5. Tanrikut C, Feldman AS, Altemus M,
et al. Adverse effects of paroxetine on
sperm. Fertil Steril 2010;94:1021-6
6. Lewis SEM, Aitken RJ. DNA damage to
spermatozoa has impacts on fertilization and
pregnancy. Cell Tissue Res 2005;322:33-41
7. Schirm E, Pedersen L, Tobi H, et al.
Drug use among fathers around time of
conception: two register based surveys
from Denmark and the Netherlands.
Pharmacoepidemiol Drug Saf
2004;13:609-13
8. Engeland A, Bramness JG,
Kjersti Daltveit A, et al. Prescription drug
use among fathers and mothers
before and during pregnancy.
A population-based cohort study of 106
000 pregnancies in Norway 2004-2006.
Br J Clin Pharmacol 2008;65:653-60
. Was one of the main reasons to
perform our study, created
our awareness.
9. De Santis M, Cesari E, Cavaliere A,
et al. Paternal exposure and counseling:
experience of a teratology information
service. Reprod Toxicol 2008;26:42-6
10. Hoeltzenbein M, Weber-Schoendorfer C,
et al. Paternal exposure to drugs -- Is
there an increased risk for congential
abnormalities?: experience of the Berlin
Institute for clinical teratology and drug
risk assessment during pregnancy.
Reprod Toxicol 2008;26:64
11. Lee C, Jin C, Mata A, et al. A pilot
study of paternal drug exposure: the
motherisk experience. Reprod Toxicol
2010;29:353-60
12. Cordier S. Evidence of a role of paternal
exposures in developmental toxicity.
Basic Clin Pharmacol Toxicol
2008;102:176-81
13. Available from: www.iadb.nl [Accessed
4 May 2011]
14. Available from: www.whocc.no/atc
[Accessed 2 August 2011]
15. Vegter S, Kolling P, Toben M, et al.
Replacing hormone therapy-is the decline
in prescribing sustained, and are
nonhormonal drugs substituted?
Menopause 2009;16:329-35
16. Tobi H, van den Berg PB, de Jong-van
den Berg LTW. The interaction
database: synergy of science and practice
in pharmacy. In: Brause RW, Hanisch E,
editors. Medical Data Analysis. Springer,
Berlin Heidelberg; New York:
2000. p. 206-11
17. Nationaal Kompas Volksgezondheid.
Available from: www.nationaalkompas.nl
[Accessed 22 September 2011]
18. Viktil K, Engeland A, Furu K. Use of
antirheumatic drugs in mothers and




19. Boyce P, Condon J, Barton J,
Corkindale C. First-time fathers’ study:
psychological distress in expectant fathers
during pregnancy. Aust N Z J Psychiatry
2007;41:718-25
20. Paulson JF, Bazemore SD. Prenatal and
postpartum depression in fathers and its
association with maternal depression.
JAMA 2010;303:1961-9
21 Green DM, Whitton JA, Stovall M, et al.
Pregnancy outcome of partners of male
survivors of childhood cancer: a report
from the childhood cancer survivor study.
J Clin Oncol 2003;21:716-21
22. Beghin D, Cournot M-P, Vauzelle C,
Elefant E. Paternal exposure to
methotrexate and pregnancy outcomes.
J Rheumatol 2011;35:628-32
23. Trojan J, Kronenberger B,
von Wagner M, Zeuzem S. Lack of birth
defects after paternal exposure to
lamivudine. J Hepatol 2002;36:571
24. Teruel C, Lopez-San Roman A, Bermejo F,
et al. Outcomes of pregnancies fathered by
inflammatory bowel disease patients
exposed to thiopurines. Am J Gastroenterol
2010;105:2003-8
25. Rajapakse R, Korelitz B, Zlatanic J, et al.
Outcome of pregnancies when fathers are
treated with 6-mercaptopurine for
inflammatory bowel disease.
Am J Gastroenterol 2000;95:684-8
26. De Santis M, Carducci B, Cavaliere A,
et al. Case Report -- Paternal exposure to
ribavirin: pregnancy and neonatal
outcome. Antivir Ther 2003;8:73-5
27. Taguchi N, Shinya I. Paternal use of
ribavirin-interferon alpha
B2 combination therapy before
conception. Can Fam Physician
2005;26:42-6
28. Liu K, Binsaleh S, Lo K, Jarvi K.
Propecia-induced spermatogenic failure:
a report of two cases. Fertil Steril
2008;90:849.e17-19
29. Patel A, Rivkees S. Case Report -- Prenatal
virilization associated with paternal
testosterone gel therapy. Int J Pediatr
Endocrinol 2010;2010:867471
30. Davis DL, Friedler G, Mattison D,
Morris R. Male-mediated tertogenesis
and other reproductive effect: biologic
and epidemiologic findings and a plea
for clinical research. Reprod Toxicol
1992;6:289-92
Affiliation
Ineke Crijns†1,2 MD MFPM, Jens Bos1,
Marissa Knol1, Sabine Straus2,3 &
Lolkje de Jong-van den Berg1
†Author for correspondence
1University of Groningen, Department of
PharmacoEpidemiology & PharmacoEconomics,
Groningen, The Netherlands
2Medicines Evaluation Board, Department of
Pharmacovigilance, Graadt van Roggeweg 500,
3531 AH Utrecht, The Netherlands
Tel: +31 0 88 2248000; Fax: +31 0 88 2248001;
E-mail: hj.crijns@cbg-meb.nl
3Erasmus Medical Center,
Department of Medical Informatics,
Rotterdam, The Netherlands
I. Crijns et al.
518 Expert Opin. Drug Saf. (2012) 11(4)
Ex
pe
rt 
O
pi
n.
 D
ru
g 
Sa
f. 
D
ow
nl
oa
de
d 
fro
m
 in
fo
rm
ah
ea
lth
ca
re
.c
om
 b
y 
U
ni
ve
rs
ity
 o
f G
ro
ni
ng
en
 o
n 
07
/0
3/
12
Fo
r p
er
so
na
l u
se
 o
nl
y.
